1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis
(
- Contribution to journal › Article
- 2022
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2021
-
Mark
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease : results from nationwide Swedish registers
(
- Contribution to journal › Article
-
Mark
Review article : exposure to microbes and risk of coeliac disease
(
- Contribution to journal › Scientific review
-
Mark
Predictors of drug survival : A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register
(
- Contribution to journal › Article
- 2020
-
Mark
Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden
(
- Contribution to journal › Article
- 2019
-
Mark
Clinical course and mortality by etiology of liver cirrhosis in Sweden : a population based, long-term follow-up study of 1317 patients
(
- Contribution to journal › Article
-
Mark
Letter : different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases
(
- Contribution to journal › Letter
- 2017
-
Mark
Long-term outcome of infliximab treatment in chronic active ulcerative colitis : a Swedish multicentre study of 250 patients
(
- Contribution to journal › Article
-
Mark
Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors' reply
(
- Contribution to journal › Letter